Carcinoma, Non-Small-Cell Lung Clinical Trial
Official title:
The Drainage Effect of a Chest Tube Plus Prophylactic Air-extraction Catheter vs Traditional Drainage Strategy in Uniportal Upper Lung Lobectomy
| NCT number | NCT04461652 |
| Other study ID # | TongiU |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | January 5, 2020 |
| Est. completion date | March 2022 |
Traditional drainage for uniportal video assisted thoracoscopic surgery (VATS) is a routine
method, usually with one or two chest tubes at intercostal incisions, but postoperative pain
due to the chest tube and unsatisfied drainage effect was noted.
In this study, the investigators are going to explore whether a prophylactic air-extraction
catheter combined with chest tube drainage may not increase complications in uniportal VATS
for upper lung lobectomy. The patients would be assigned to two arms, one with a prophylactic
air-extraction catheter combined with chest tube, and another with two chest tubes, and the
effect of the combined drainage strategy will be evaluated.
| Status | Recruiting |
| Enrollment | 400 |
| Est. completion date | March 2022 |
| Est. primary completion date | November 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Patients undergoing uniport VATS for left / right upper lobectomy in Shanghai Pulmonary Hospital Exclusion Criteria: - preoperative presence of any unstable systemic disease, such as active infection, uncontrolled hypertension, or unstable angina pectoris; - previous ipsilateral thoracic surgery; - preoperative X-ray findings of pneumonia or atelectasis; - bleeding tendency; - anticoagulant use; - pregnancy or breastfeeding; - converted to open chest; - the patient underwent pneumonectomy or segmental resection or wedge resection; - severe adhesion occurred during the operation |
| Country | Name | City | State |
|---|---|---|---|
| China | Shanghai Pulmonary Hospital | Shanghai | Shanghai |
| Lead Sponsor | Collaborator |
|---|---|
| Tongji University |
China,
Bulgarelli Maqueda L, García-Pérez A, Minasyan A, Gonzalez-Rivas D. Uniportal VATS for non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2019 Oct 15. doi: 10.1007/s11748-019-01221-4. [Epub ahead of print] Review. — View Citation
Liu CY, Hsu PK, Leong KI, Ting CK, Tsou MY. Is tubeless uniportal video-assisted thoracic surgery for pulmonary wedge resection a safe procedure? Eur J Cardiothorac Surg. 2020 Mar 17. pii: ezaa061. doi: 10.1093/ejcts/ezaa061. [Epub ahead of print] — View Citation
Mun M, Nakao M, Matsuura Y, Ichinose J, Nakagawa K, Okumura S. Video-assisted thoracoscopic surgery lobectomy for non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2018 Nov;66(11):626-631. doi: 10.1007/s11748-018-0979-x. Epub 2018 Jul 30. Review. — View Citation
Zhang JT, Dong S, Chu XP, Lin SM, Yu RY, Jiang BY, Liao RQ, Nie Q, Yan HH, Yang XN, Wu YL, Zhong WZ. Randomized Trial of an Improved Drainage Strategy Versus Routine Chest Tube After Lung Wedge Resection. Ann Thorac Surg. 2020 Apr;109(4):1040-1046. doi: 1 — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | pneumothorax incidence | The incidence of pneumothorax on day 1 after operation | 24-30 hours after surgery | |
| Secondary | pain scores | pain scores collected after surgery | 1day, 3days and 30 days after surgery | |
| Secondary | Extubation time | Extubation time after operation | within 30 days after surgery | |
| Secondary | Total volume | Total volume of pleural effusion on the first day after operation | 1 day after surgery |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
| Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
| Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
| Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
| Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
| Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
| Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
| Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
| Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
| Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
| Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
| Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
| Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |